These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 1615925)
41. Aberrant expression of insulin-like growth factor-2 (IGF-2) in Philadelphia chromosome negative chronic myeloproliferative disorders. Bock O; Tessema M; Serinsöz E; von Wasielewski R; Büsche G; Kreipe H Leuk Res; 2004 Nov; 28(11):1145-51. PubMed ID: 15380337 [TBL] [Abstract][Full Text] [Related]
42. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms. Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163 [TBL] [Abstract][Full Text] [Related]
43. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders. Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372 [TBL] [Abstract][Full Text] [Related]
44. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Wang SA; Hasserjian RP; Tam W; Tsai AG; Geyer JT; George TI; Foucar K; Rogers HJ; Hsi ED; Rea BA; Bagg A; Bueso-Ramos CE; Arber DA; Verstovsek S; Orazi A Haematologica; 2017 Aug; 102(8):1352-1360. PubMed ID: 28495918 [TBL] [Abstract][Full Text] [Related]
45. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. Aboudola S; Murugesan G; Szpurka H; Ramsingh G; Zhao X; Prescott N; Tubbs RR; Maciejewski JP; Hsi ED Am J Surg Pathol; 2007 Feb; 31(2):233-9. PubMed ID: 17255768 [TBL] [Abstract][Full Text] [Related]
46. [Clonality and stem cell defects in the molecular pathology of chronic myeloproliferative disorders]. Kreipe H; Radzun HJ; Bartels H; von Heyden HW; Löffler H; Parwaresch MR Verh Dtsch Ges Pathol; 1990; 74():49-64. PubMed ID: 1708635 [TBL] [Abstract][Full Text] [Related]
47. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications. Panani AD Cancer Lett; 2007 Sep; 255(1):12-25. PubMed ID: 17383090 [TBL] [Abstract][Full Text] [Related]
48. Megakaryopoiesis in chronic myeloproliferative diseases. A morphometric evaluation with special emphasis on primary thrombocythemia. Thiele J; Funke S; Holgado S; Choritz H; Georgii A Anal Quant Cytol; 1984 Sep; 6(3):155-67. PubMed ID: 6594964 [TBL] [Abstract][Full Text] [Related]
49. bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment. Tefferi A; Barbui T Mayo Clin Proc; 2005 Sep; 80(9):1220-32. PubMed ID: 16178503 [TBL] [Abstract][Full Text] [Related]
50. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm. Salem A; Loghavi S; Tang G; Huh YO; Jabbour EJ; Kantarjian H; Wang W; Hu S; Luthra R; Medeiros LJ; Khoury JD Am J Hematol; 2017 Jun; 92(6):520-528. PubMed ID: 28253536 [TBL] [Abstract][Full Text] [Related]
52. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders]. Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237 [TBL] [Abstract][Full Text] [Related]
53. Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes. Champion KM; Gilbert JG; Asimakopoulos FA; Hinshelwood S; Green AR Br J Haematol; 1997 Jun; 97(4):920-6. PubMed ID: 9217198 [TBL] [Abstract][Full Text] [Related]
54. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression. Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343 [TBL] [Abstract][Full Text] [Related]
55. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940 [TBL] [Abstract][Full Text] [Related]
56. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Primignani M; Barosi G; Bergamaschi G; Gianelli U; Fabris F; Reati R; Dell'Era A; Bucciarelli P; Mannucci PM Hepatology; 2006 Dec; 44(6):1528-34. PubMed ID: 17133457 [TBL] [Abstract][Full Text] [Related]
57. [Histomorphologic findings of the bone marrow in chronic myeloproliferative diseases]. Thiele J; Fischer R Z Hautkr; 1989 Oct; 64(10):903-4, 909-12. PubMed ID: 2686247 [TBL] [Abstract][Full Text] [Related]
58. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Bacher U; Haferlach T; Kern W; Hiddemann W; Schnittger S; Schoch C Ann Hematol; 2005 Apr; 84(4):250-7. PubMed ID: 15692838 [TBL] [Abstract][Full Text] [Related]